SBI to Initiate UK PII Study of 5-ALA for Prevention of Postoperative Cardiac Output Reduction

SBI Pharmaceuticals will start a PII clinical study of 5-aminolevulinic acid (5-ALA) in the UK to investigate its efficacy for preventing a reduction in cardiac output after heart bypass surgery, in partnership with the University of Oxford, its parent company...read more